Immunological Medicines for Rabbits
Immunological veterinary medicinal products, including vaccines, are authorised for rabbits.
Name | Description | Marketing Authorisation Holder | License Number | License Date | Animal | Further Information |
---|---|---|---|---|---|---|
CUNIVAK COMBO |
Myxomatose, Rabbit Haemorrhagic Disease (RHD) |
IDT Biologika GmbH |
PEI.V.07962.01.1 | 05.08.2009 | Kaninchen | |
CUNIVAK ENT |
Epizootische Enteropathie |
IDT Biologika GmbH |
PEI.V.11641.01.1 | 17.07.2013 | Kaninchen | |
CUNIVAK JET |
Myxomatose |
IDT Biologika GmbH |
43a/92 | 14.10.2003 | Kaninchen | |
CUNIVAK MYXO |
Myxomatose |
IDT Biologika GmbH |
42a/92 | 14.10.2003 | Kaninchen | |
CUNIVAK PAST |
Kaninchenschnupfen |
IDT Biologika GmbH |
4a/96 | 01.04.1997 | Kaninchen | |
CUNIVAK RHD |
Rabbit Haemorrhagic Disease (RHD) |
IDT Biologika GmbH |
206a/92 | 11.05.2004 | Kaninchen | |
Eravac |
Rabbit Haemorrhagic Disease (RHD) |
Laboratorios Hipra S.A., Spanien |
EU/2/16/199-/001-002 | 26.09.2016 | Kaninchen | |
Filavac VHD K C+V |
Rabbit Haemorrhagic Disease (RHD) |
FILAVIE, Roussay, Frankreich |
PEI.V.11900.01.1 | 13.03.2017 | Kaninchen | |
Nobivac Myxo-RHD |
Myxomatose, Rabbit Haemorrhagic Disease (RHD) |
Intervet International BV, Niederlande |
EU/2/11/132/002-004 | 07.09.2011 | Kaninchen | |
Nobivac Myxo-RHD PLUS |
Myxomatose, Rabbit Haemorrhagic Disease (RHD) |
Intervet International B.V., Niederlande |
EU/2/19/244/001-003 | 19.11.2019 | Kaninchen | |
RIKA - VACC RHD |
Rabbit Haemorrhagic Disease (RHD) |
Ecuphar NV, Belgien |
200a/91 | 04.09.2003 | Kaninchen | |
RIKA-VACC Duo |
Myxomatose, Hämorrhagische Krankheit (RHD) |
Ecuphar NV, Belgien |
PEI.V.03071.01.1 | 12.06.2008 | Kaninchen | |
RIKA-VACC Myxo sc |
Myxomatose |
Ecuphar NV, Belgien |
PEI.V.03157.01.1 | 12.06.2008 | Kaninchen |
Hints
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 477 in BAnz AT 16.02.2021 B7.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 01.03.2021